Talkiatry Funding, Investors & Competitors

Talkiatry has raised $452M across 5 funding rounds, most recently a $210M Series D in February 2026.

Last Talkiatry funding round

$210M

Series D · Feb 2026

Cumulative funding Talkiatry raised

$452M

across 5 funding rounds

Key investors in Talkiatry

  • Left Lane Capital
  • Andreessen Horowitz
  • Perceptive Advisors
  • Blisce
  • Sofina
  • Relevance Ventures
  • Cold Start Ventures
  • GreyMatter

Talkiatry Overview

About Talkiatry

Talkiatry is a virtual psychiatry provider offering in-network services through over 300 licensed psychiatrists. It delivers evaluations, diagnoses, treatment plans, and medication management for conditions including anxiety, depression, ADHD, and substance use disorders.


Founded

2019

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2C

Revenue model

Services

Talkiatry Funding History

Talkiatry has raised a total of $452M across 5 funding rounds.

Talkiatry's first fundraising round was a $20M Series A in July 2021. The most recent completed round was a $210M Series D in February 2026.

Talkiatry funding rounds

Talkiatry funding rounds
DateStageInvestorsRaisedDeal Summary
Feb 2026Series DPerceptive Advisors (lead); Left Lane Capital; Andreessen Horowitz; Sofina; Blisce$210MTalkiatry, a full-stack telepsychiatry provider, raised an oversubscribed $210 million Series D funding round on February 12, 2026, led by Perceptive Advisors with participation from Sofina, Andreessen Horowitz (a16z), blisce/, and Left Lane Capital, plus a debt facility from Banc of California, bringing total funding to over $400 million. The company employs over 800 full-time W2 psychiatrists and 300 therapists, delivering 3 million patient visits to date, and positions itself as the nation's largest private employer of psychiatrists. It operates in 45 states, is in-network with over 100 insurers covering 170 million lives, and partners with 50+ health systems via its Mindshare Partner Program to serve as an outsourced psychiatry department. Talkiatry's model emphasizes employed clinicians, proprietary AI-powered technology for back-office automation, patient engagement, and clinical support, and insurance-covered virtual visits for conditions like anxiety, depression, bipolar disorder, OCD, PTSD, and postpartum depression. Clinical outcomes include 87% of anxiety patients and 86% of depression patients showing symptom improvement after two visits, 60% lower dropout rates than industry benchmarks, 76 NPS rating, and 22% higher therapeutic alliance ratings. The company reports payer savings of up to $700 per member per month through reduced emergency visits and admissions, with no subscription models or pharmacy affiliations. The funding will fuel expansion across acuity spectrum, technology investments including AI to reduce clinician burnout by 80%, and scaling as the in-network psychiatry partner for health systems, payers, and employers. Talkiatry was ranked on Deloitte Technology Fast 500 in 2025 and recognized by Fortune and Great Place to Work. CEO Robert Krayn stated no imminent IPO plans, focusing on enterprise-scale operations; the company declined to disclose valuation or profitability progress.
Jun 2024Series CAndreessen Horowitz (lead); Perceptive Advisors$130MTalkiatry is a New York City-based telepsychiatry provider founded in 2020 that delivers high-quality, in-network psychiatric care for conditions including ADHD, anxiety, bipolar disorder, depression, OCD, and PTSD to children and adults across 43 states. The company employs over 300 full-time W-2 psychiatrists, distinguishing it from peers that often use contractors, and partners with more than 60 health plans such as UnitedHealthcare, Aetna, Blue Cross Blue Shield, Cigna, and Humana, providing access to over 70% of commercially insured individuals. It has delivered over one million patient visits, with published data showing clinically significant improvements in depression and anxiety symptoms. On June 18, 2024, Talkiatry announced a $130 million Series C funding round comprising equity and debt to expand its value-based care model, scale operations, reduce total cost of care, improve health outcomes, and pursue growth including potential acquisitions and an eventual IPO. The equity portion was led by Andreessen Horowitz (a16z) with participation from Perceptive Advisors, and debt financing came from Banc of California. This brings Talkiatry's total funding to $245 million, following a $75 million Series B in September 2023 and prior investments from Left Lane Capital and blisce. Talkiatry demonstrates strong outcomes in value-based arrangements, including a 68% reduction in patient hospitalizations, 32% fewer emergency room visits, and $700 in monthly savings per member on total cost of care compared to peers for a leading national health plan cohort. Andreessen Horowitz highlighted Talkiatry's ability to mainstream outcomes-based psychiatric care and risk-based payment models through affordable, high-quality treatment and expanding payer partnerships. The company integrates with electronic health records for referrals and focuses on underserved populations while positioning for broader adoption of value-based behavioral health care amid ongoing telemental health deal activity.
Jul 2022Series BBlisce (lead); Yousif Al-Dujaili; Left Lane Capital; Transform Capital; GreyMatter$75M-
Jan 2022Series ALeft Lane Capital (lead)$17M-
Jul 2021Series ALeft Lane Capital (lead); Cold Start Ventures; Relevance Ventures; Richard Park$20MTalkiatry raised $20 million in a Series A funding round announced around July 28, 2021, comprising an initial $5 million led by Sikwoo Capital Partners (announced earlier in February 2021) and an additional $15 million led by Left Lane Capital, with participation from Relevance Ventures and Dr. Richard Park, founder and former CEO of CityMD. The funding aimed to build out its proprietary technology platform and expand its geographic footprint into additional states in the Northeast, Mid-Atlantic, and South starting in 2022. Founded in 2020 by Robert Krayn and Dr. Georgia Gaveras, Talkiatry operates as an in-network psychiatric care provider offering both in-person and virtual mental health services, employing psychiatrists and using a technology-driven model to address psychiatrist shortages while meeting insurer requirements. At the time of the Series A, Talkiatry employed more than 30 psychiatrists and 40 total providers, having completed over 30,000 patient visits since launch. The company had partnered with major insurers including UnitedHealthcare, Aetna, Humana, Cigna, and Blue Cross Blue Shield, positioning it to provide accessible care without out-of-pocket costs beyond typical copays. Its model emphasizes ongoing care, starting with virtual surveys for matching patients to psychiatrists, followed by diagnosis, therapy, medication management, and tools like VR. Talkiatry differentiates itself in the behavioral health space by focusing exclusively on in-network psychiatry services, competing with platforms like Cerebral, Headway, and Uplift, while contrasting with better-capitalized players like Ginger and Lyra Health.

Who has invested in Talkiatry?

11 investors have backed Talkiatry across its funding rounds, including Left Lane Capital, Andreessen Horowitz, Perceptive Advisors, Blisce, Sofina and Relevance Ventures.

Lead investors include Perceptive Advisors, Andreessen Horowitz, Blisce and Left Lane Capital.


Talkiatry Investors

Investors in Talkiatry by funding rounds participated
InvestorHQRoundsRoleFirst check
Left Lane CapitalUnited StatesNew York City, NY4LeadJul 2021
Andreessen HorowitzUnited StatesSan Francisco, CA2LeadJun 2024
Perceptive AdvisorsUnited StatesNew York City, NY2LeadJun 2024
BlisceUnited StatesNew York City, NY2LeadJul 2022
Cold Start VenturesUnited StatesNew York City, NY1ParticipantJul 2021
Relevance VenturesUnited StatesUnited States1ParticipantJul 2021
Yousif Al-DujailiUnited StatesNew York City, NY1ParticipantJul 2022
Richard ParkUnited StatesNew York City, NY1ParticipantJul 2021
Transform CapitalUnited StatesSan Francisco, CA1ParticipantJul 2022

This data is available for Pro users. Sign up to see all 11 Talkiatry investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Talkiatry Competitors

Talkiatry competitors include listed companies like Hims and Teladoc, and private ones like Cerebral, Grow Therapy, Headway and Nourish.

Public and private companies comparable to Talkiatry
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
HimsUnited StatesUnited StatesPublicly listed$2.3B$178M$6.5B2.4x
CerebralUnited StatesSan Francisco, CAPrivate--$4.8B-
Grow TherapyUnited StatesNew York City, NYPrivate$1B-$3B-
HeadwayUnited StatesNew York City, NYPrivate--$2.3B-
NourishUnited StatesNew York City, NYPrivate$160M-$1.8B10.9x
TeladocUnited StatesUnited StatesPublicly listed$2.5B$124M$1.1B0.6x

Talkiatry Public Comps

Talkiatry is still privately-owned, but its public comps include Humana Inc., Max Healthcare Institute, Oscar Health, Hims, Doximity, ACADIA Pharmaceuticals, Compass Pathways, Ping An Healthcare, JMDC and GoodRx.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Humana Inc.$130B$3B0.4x0.3x17.8x16.6x
Max Healthcare Institute$858M$232M12.6x10.2x46.5x36.8x
Oscar Health$12B($391M)0.5x0.4x(15.9x)12.8x
Hims$2.3B$178M3.1x2.4x40.4x23.9x
Doximity$645M$229M6.3x6.2x17.7x11.9x
ACADIA Pharmaceuticals$1.1B$119M3.6x3.2x32.3x33.6x
Compass Pathways-($293M)--(5.8x)(8.4x)
Ping An Healthcare$815M$52M0.9x0.9x13.4x16.9x

This data is available for Pro users. Sign up to see all Talkiatry competitors and their valuation data.

Start Free Trial

Common questions about Talkiatry

When was Talkiatry founded?Talkiatry was founded in 2019.
Where is Talkiatry headquartered?Talkiatry is headquartered in New York City, NY, United States.
Is Talkiatry publicly listed?No, Talkiatry is a private, VC-backed company.
How much funding has Talkiatry raised?Talkiatry has raised $452M across 5 funding rounds.
What was Talkiatry's last funding round?Talkiatry's last funding round was a $210M Series D in February 2026, led by Perceptive Advisors.
Who are Talkiatry's investors?Talkiatry's investors include Left Lane Capital, Andreessen Horowitz, Perceptive Advisors, Blisce, Cold Start Ventures, Relevance Ventures, Yousif Al-Dujaili, Richard Park, Transform Capital, Sofina and 1 other.
Which companies are comparable to Talkiatry?Companies comparable to Talkiatry include Hims, Cerebral, Grow Therapy, Headway, Nourish and Teladoc.

See companies similar to Talkiatry

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial